Szilagyi Agnes, Blasko Bernadett, Szilassy Denes, Fust George, Sasvari-Szekely Maria, Ronai Zsolt
Institute of Medical Chemistry, Molecular Biology and Pathobiochemistry, Semmelweis University, Budapest, Hungary.
BMC Genet. 2006 Jan 10;7:1. doi: 10.1186/1471-2156-7-1.
The fourth component of human complement (C4), an essential factor of the innate immunity, is represented as two isoforms (C4A and C4B) in the genome. Although these genes differ only in 5 nucleotides, the encoded C4A and C4B proteins are functionally different. Based on phenotypic determination, unbalanced production of C4A and C4B is associated with several diseases, such as systemic lupus erythematosus, type 1 diabetes, several autoimmune diseases, moreover with higher morbidity and mortality of myocardial infarction and increased susceptibility for bacterial infections. Despite of this major clinical relevance, only low throughput, time and labor intensive methods have been used so far for the quantification of C4A and C4B genes.
A novel quantitative real-time PCR (qPCR) technique was developed for rapid and accurate quantification of the C4A and C4B genes applying a duplex, TaqMan based methodology. The reliable, single-step analysis provides the determination of the copy number of the C4A and C4B genes applying a wide range of DNA template concentration (0.3-300 ng genomic DNA). The developed qPCR was applied to determine C4A and C4B gene dosages in a healthy Hungarian population (N = 118). The obtained data were compared to the results of an earlier study of the same population. Moreover a set of 33 samples were analyzed by two independent methods. No significant difference was observed between the gene dosages determined by the employed techniques demonstrating the reliability of the novel qPCR methodology. A Microsoft Excel worksheet and a DOS executable are also provided for simple and automated evaluation of the measured data.
This report describes a novel real-time PCR method for single-step quantification of C4A and C4B genes. The developed technique could facilitate studies investigating disease association of different C4 isotypes.
人类补体第四成分(C4)是先天免疫的重要因子,在基因组中以两种异构体(C4A和C4B)形式存在。尽管这些基因仅在5个核苷酸上存在差异,但编码的C4A和C4B蛋白在功能上有所不同。根据表型测定,C4A和C4B的不平衡产生与多种疾病相关,如系统性红斑狼疮、1型糖尿病、多种自身免疫性疾病,此外还与心肌梗死的较高发病率和死亡率以及细菌感染易感性增加有关。尽管具有如此重要的临床意义,但迄今为止,仅使用了低通量、耗时且费力的方法来定量C4A和C4B基因。
开发了一种新型定量实时PCR(qPCR)技术,采用基于TaqMan的双链方法,可快速准确地定量C4A和C4B基因。可靠的单步分析能够在广泛的DNA模板浓度范围(0.3 - 300 ng基因组DNA)内测定C4A和C4B基因的拷贝数。将开发的qPCR应用于测定匈牙利健康人群(N = 118)中的C4A和C4B基因剂量。将获得的数据与该人群早期研究的结果进行了比较。此外,通过两种独立方法对一组33个样本进行了分析。在所采用技术测定的基因剂量之间未观察到显著差异,证明了新型qPCR方法的可靠性。还提供了一个Microsoft Excel工作表和一个DOS可执行文件,用于对测量数据进行简单自动评估。
本报告描述了一种用于单步定量C4A和C4B基因的新型实时PCR方法。所开发的技术可促进对不同C4同种型疾病关联的研究。